Moderna (MRNA) Change in Receivables (2018 - 2026)

Moderna (MRNA) has reported Change in Receivables for 9 consecutive years, with -$53.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Receivables fell 76.67% year-over-year to -$53.0 million in Q2 2026; TTM through Jun 2026 was -$13.0 million, a 88.7% increase from a year earlier, with the FY2025 full-year figure at -$156.0 million, up 70.79% from the prior year.
• Change in Receivables was -$53.0 million for Q2 2026 at Moderna, up from -$114.0 million in the prior quarter.
• Over five years, Change in Receivables peaked at $1.6 billion in Q3 2023 and troughed at -$1.3 billion in Q4 2022.
• A 5-year average of -$174.4 million and a median of -$193.0 million in 2023 frame the typical range for Change in Receivables.
• The widest YoY moves for Change in Receivables: up 40750.0% in 2023, down 27100.0% in 2023.
• Over 5 years, Change in Receivables stood at -$1.3 billion in 2022, then increased by 25.65% to -$974.0 million in 2023, then decreased by 23.82% to -$1.2 billion in 2024, then rose by 28.77% to -$859.0 million in 2025, then jumped by 93.83% to -$53.0 million in 2026.
• The last three Change in Receivables figures came in at -$53.0 million (Q2 2026), -$114.0 million (Q1 2026), and -$859.0 million (Q4 2025), per Business Quant data.